Ratings PetMed Express, Inc.

Equities

PETS

US7163821066

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
4.02 ^USD	-0.74%		-2.19%	-46.83%

04-15	Earnings Flash (PETS) PETMED EXPRESS Posts Q3 Revenue $65.3M	MT
04-15	PetMed Express, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company is in a robust financial situation considering its net cash and margin position.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.12 for the 2024 fiscal year.
The company appears to be poorly valued given its net asset value.
The company is one of the best yield companies with high dividend expectations.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
PETMED EXPRESS, INC.	-46.83%	81.99M		C
RAIA DROGASIL S.A.	-12.86%	8.57B		B
AIN HOLDINGS INC.	+32.95%	1.32B		-
QOL HOLDINGS CO., LTD.	+6.76%	419M		-
NIHON CHOUZAI CO.,LTD.	+5.93%	282M		-
SALUS, LJUBLJANA, D. D.	+10.56%	224M	-	-
GREEN CROSS HEALTH LIMITED	-8.26%	85.07M	-	-
MEDICAL IKKOU GROUP CO.,LTD.	+20.94%	59.57M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes